XML 87 R63.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Commitments and Contingencies - Narrative (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Jan. 01, 2021
USD ($)
shares
Aug. 31, 2023
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Mar. 31, 2024
term
Liability For Sale of Future Royalties [Line Items]              
Research and development     $ 314,819,000 $ 79,490,000 $ 470,791,000 $ 142,951,000  
Pittsburgh Centre Avenue Lease Agreement              
Liability For Sale of Future Royalties [Line Items]              
Lease agreement, term (in months)             122 months
Option to extend, term | term             1
Extension term (in months)             60 months
Pittsburgh Centre Avenue Lease Agreement | Minimum              
Liability For Sale of Future Royalties [Line Items]              
Annual commitments     1,859,000   1,859,000    
Pittsburgh Centre Avenue Lease Agreement | Maximum              
Liability For Sale of Future Royalties [Line Items]              
Annual commitments     $ 2,373,000   2,373,000    
Moda Agreement              
Liability For Sale of Future Royalties [Line Items]              
Eligible commercial milestone payments   $ 23,000,000          
Eligible develoment and regulatory milestone payments   $ 25,200,000          
Moda Pharmaceuticals LLC              
Liability For Sale of Future Royalties [Line Items]              
Research and development       $ 0 850,000 $ 0  
Moda Pharmaceuticals LLC | Moda Agreement              
Liability For Sale of Future Royalties [Line Items]              
Eligible development milestone payments $ 81,612,000            
Eligible commercial milestone payments $ 30,171,000            
Initial term of agreement (in years) 4 years            
Moda Pharmaceuticals LLC | License agreement | Moda Agreement              
Liability For Sale of Future Royalties [Line Items]              
Payment for license agreement $ 2,700,000            
Issuance of common shares as payment for assets (in shares) | shares 37,836            
Issuance of common shares as payment for assets $ 3,243,000            
Research and Development Arrangement              
Liability For Sale of Future Royalties [Line Items]              
Research commitments         $ 0